DEA Judge Halts Cannabis Rescheduling, Clock Now Ticks

October 4, 2026

Photo by Towfiqu barbhuiya via Pexels.

For a process that has already dragged on for more than three years, the timing could hardly have been worse. On September 29, 2026, DEA Chief Administrative Law Judge Derek C. Julius issued a stay halting the federal marijuana rescheduling proceeding at the exact moment his recommendation to DEA Administrator Terry Cole was expected to land. That recommendation -- nonbinding but closely watched as the last real checkpoint before a final agency decision -- was supposed to settle whether cannabis stays in Schedule I alongside heroin or moves to Schedule III alongside ketamine and anabolic steroids.

The stay didn't come out of nowhere. One day earlier, on September 28, three groups aligned against rescheduling -- DUID Victim Voices, Kenneth Finn M.D., and the National Drug and Alcohol Screening Association -- filed a motion pointing to a freshly released Government Accountability Office report on gaps in federal scheduling procedure. Judge Julius granted the pause almost immediately, and markets reacted just as fast. Shares tied to multi-state cannabis operators dropped sharply in after-hours trading and continued falling the next day, erasing gains built up over months of anticipation.

None of this happens in a vacuum. The industry has been counting down to this recommendation for a specific reason: a Schedule III reclassification would end the application of Section 280E, the tax code provision that bars cannabis businesses from deducting ordinary expenses because the plant remains federally illegal. With the clock already running on a years-behind process, a few weeks of delay now carries outsized weight.

What Happened on September 29

Photo by VBlock via Pixabay.

The stay applies to DEA Docket No. 1362, also tracked as Hearing Docket No. 26-96, the formal administrative proceeding examining whether marijuana should move from Schedule I to Schedule III of the Controlled Substances Act. Judge Julius, who has presided over the hearing since it began, granted the stay in direct response to a motion filed just one day earlier by three groups that have consistently opposed rescheduling: DUID Victim Voices, physician Kenneth Finn, and the National Drug and Alcohol Screening Association. All three have built their advocacy around concerns tied to impaired driving detection and workplace drug testing, arguing that a lower schedule would complicate enforcement and liability in those areas.

Under the terms of the stay, the federal government now has until October 13 to respond to the motion. That response will determine whether the proceeding resumes on anything like its prior schedule or faces further delay while Judge Julius weighs the arguments raised.

What makes this stay consequential rather than routine is exactly what it interrupts. Julius was understood to be close to issuing his recommendation to DEA Administrator Terry Cole -- the document that would formally advise the agency on whether the scientific and legal record supports Schedule III placement. That recommendation doesn't bind Cole or the DEA, but it carries real weight as the capstone of an 11-day evidentiary hearing and the only point in this docket where the presiding judge puts his own analysis on the record. Halting the process at this exact juncture means the industry and federal officials alike are now waiting on a procedural fight rather than a substantive ruling, with no clear date for when that recommendation might actually surface.

The GAO Report That Triggered the Stay

Photo by myrfa via Pixabay.

The motion that triggered the stay leaned heavily on a GAO report released September 23, 2026, examining whether DEA's scheduling decisions align with recommendations from federal health regulators, and whether both agencies have adequate internal procedures for making those calls in the first place. The title and framing of the report focus on process, not outcome -- GAO wasn't asked to weigh in on cannabis specifically, and it didn't.

Its core finding is that DEA lacks a comprehensive policy spelling out who is responsible for what during a scheduling action, and what procedures staff should follow from start to finish. GAO raised a parallel concern about the FDA side of the equation: the agency doesn't have documented procedures specifying how its staff are supposed to conduct the scientific and medical evaluations that feed into a scheduling recommendation. That matters practically because without written procedures, institutional knowledge lives in the heads of specific employees -- and if those people leave or retire, the process can lose continuity in ways that are hard to reconstruct later.

Attorneys following the rescheduling docket have been quick to note what the report does not say. It predates the current marijuana proceeding and wasn't written with cannabis in mind -- it's a general audit of how DEA and FDA handle scheduling decisions across all controlled substances. It doesn't conclude that either agency broke the law, and it doesn't challenge or reject the scientific findings that supported the 2023 recommendation to move marijuana to Schedule III. In other words, the report identifies a documentation and governance gap, not a flaw in the cannabis-specific record that's been built over the past three years of hearings.

A Process Already Years in the Making

Photo by Yash Lucid via Pexels.

This rescheduling push has been running since August 2023, when a formal recommendation moved marijuana toward Schedule III based on an eight-factor analysis of its medical use, abuse potential, and safety profile. DEA accepted that recommendation as grounds to open its own rulemaking, and formal hearings were originally scheduled to begin in January 2025. Those hearings didn't happen on time, delayed by procedural disputes over who would be allowed to participate and how cross-examination would work.

When the hearing finally got underway, it ran 11 days and concluded July 15, 2026, under Judge Julius's supervision. Post-hearing briefs from the parties were filed by August 17, and more than 2,500 pages of hearing transcripts were released to the public on August 25 -- a substantial record covering testimony from medical experts, researchers, and representatives of groups on both sides of the question. Notably, NORML and several other advocacy organizations that wanted to participate directly in the hearing were denied that opportunity, a decision that drew criticism from reform advocates who argued the proceeding excluded voices central to the policy debate.

It's worth separating this docket from a related but distinct action: in April, Attorney General Todd Blanche issued an order moving FDA-approved marijuana drug products and state-licensed medical marijuana programs to Schedule III on a narrower basis. That order operates independently of the broader rescheduling docket now before Judge Julius, and the current stay does not affect it -- a distinction that matters for companies trying to figure out exactly what is and isn't paused.

Why the Calendar Matters: 280E and the November 6 Deadline

Photo by Polina Tankilevitch via Pexels.

DEA's own hearing rules build in a mandatory waiting period: a final order can't take effect until at least 55 days after a recommendation is issued. Working backward from a goal of getting a broader Schedule III rule in place before the end of 2026, that math meant Judge Julius's recommendation needed to reach the parties by roughly November 6. Miss that date, and the entire timeline for finishing the process within the year starts to look shaky.

That deadline isn't just an abstract bureaucratic marker -- it's directly tied to money. Operators have structured tax planning and in some cases investor communications around the expectation that Section 280E relief could arrive this year, once marijuana formally moves to Schedule III and stops being treated as a Schedule I substance for federal tax purposes. Every multi-state operator currently paying effective tax rates well above what ordinary businesses face has a direct financial stake in whether that November date holds.

The October 13 deadline for the government's response to the stay motion is now the most concrete date on the calendar. If DEA counsel responds quickly and Judge Julius lifts the stay without much delay, the November timeline could still be salvageable, if tight. If the stay drags on, or if Julius uses the GAO findings as grounds for a more extended review, the 2026 deadline for 280E relief becomes increasingly difficult to hit, pushing the financial benefit operators have been banking on further into the future.

Markets Flinch: MSOS and MSO Stocks Slide

Cannabis stocks slid across the board after a federal judge paused the DEA's rescheduling process, with Trulieve hit hardest at -14% and Canopy Growth the least affected at -3.79%.

Cannabis equities didn't wait for clarity -- they sold off within hours of the stay becoming public. The AdvisorShares Pure US Cannabis ETF, traded under the ticker MSOS and widely used as a proxy for the sector, fell as much as 8% in after-hours trading on September 29. Trulieve, one of the largest multi-state operators by revenue, dropped roughly 9% in that same extended session before falling further, closing down about 14% on September 30 once full trading resumed.

MSOS itself was down about 9% on September 30, confirming that the after-hours move wasn't a temporary overreaction but a reset in how investors were pricing rescheduling risk. The pain spread beyond the US-focused operators too: Canopy Growth fell 3.79% and Curaleaf dropped 4.94% in the sessions that followed, showing the selloff wasn't confined to companies with the heaviest 280E exposure.

The size of these moves says something important about how this sector trades right now. Cannabis stocks have become almost a direct proxy for rescheduling headlines, rising and falling on procedural developments that don't actually resolve the underlying question of Schedule I versus Schedule III. A stay is not a denial, and it's not a ruling on the merits -- but investors treated it as meaningfully bad news anyway, reflecting just how much of current valuations are built on the assumption that 280E relief is coming, and coming soon. That sensitivity cuts both ways: it means positive procedural news could produce just as sharp a rally if the stay lifts cleanly in October.

It's worth being precise about what actually happened here. Judge Julius paused a proceeding; he didn't end it, and nothing in the GAO report speaks to the scientific or medical case for Schedule III built back in 2023 or that was tested across 11 days of hearings this summer. The report is a governance critique aimed at how DEA and FDA document their internal processes generally -- it doesn't allege wrongdoing on this specific docket, and it doesn't give Judge Julius or Administrator Cole new grounds to reject the record that's already been assembled.

That said, procedural delays have real consequences when they collide with a hard calendar. October 13 is now the date that matters most: the government's response to the stay motion will signal whether the November 6 target for a recommendation -- and the 2026 timeline for Schedule III relief under Section 280E -- remains realistic or whether operators should start planning around a longer wait.

For businesses and investors watching this closely, the sensible read is to treat this as a delay worth tracking, not evidence the process is collapsing. Markets will likely keep overreacting to every docket filing in both directions until there's a final order on the books. In the meantime, state law continues to govern day-to-day operations regardless of what happens at DEA, so anyone affected should confirm with their own counsel exactly how a federal rescheduling outcome -- whenever it arrives -- would interact with their specific state's licensing and tax rules.